Search

Author/Creator Chyla, Brenda

2. Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. Issue 8 (16th August 2018)

Authors:
Chyla, Brenda; Daver, Naval; Doyle, Kelly; McKeegan, Evelyn; Huang, Xin; Ruvolo, Vivian; Wang, Zixing; Chen, Ken; Souers, Andrew; Leverson, Joel; Potluri, Jalaja; Boghaert, Erwin; Bhathena, Anahita; Konopleva, Marina; Popovic, Relja
Journal:
American journal of hematology
Issue:
Volume 93:Issue 8(2018:Aug.)
Page Start:
E202
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Integrated Mechanistic Model of Minimal Residual Disease Kinetics With Venetoclax Therapy in Chronic Lymphocytic Leukemia. Issue 2 (6th September 2020)

Authors:
Gopalakrishnan, Sathej; Wierda, William; Chyla, Brenda; Menon, Rajeev; Miles, Dale; Humerickhouse, Rod; Awni, Walid; Salem, Ahmed Hamed; Mensing, Sven; Freise, Kevin J.
Journal:
Clinical pharmacology & therapeutics
Issue:
Volume 109:Issue 2(2021)
Page Start:
424
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine. Issue 8 (10th March 2022)

Authors:
Pratz, Keith W.; Jonas, Brian A.; Pullarkat, Vinod; Recher, Christian; Schuh, Andre C.; Thirman, Michael J.; Garcia, Jacqueline S.; DiNardo, Courtney D.; Vorobyev, Vladimir; Fracchiolla, Nicola S.; Yeh, Su-Peng; Jang, Jun Ho; Ozcan, Muhit; Yamamoto, Kazuhito; Illes, Arpad; Zhou, Ying; Dail, Moniq...
Journal:
Journal of clinical oncology
Issue:
Volume 40:Issue 8(2022)
Page Start:
855
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Issue 36 (20th December 2021)

Authors:
Al-Sawaf, Othman; Zhang, Can; Lu, Tong; Liao, Michael Z.; Panchal, Anesh; Robrecht, Sandra; Ching, Travers; Tandon, Maneesh; Fink, Anna-Maria; Tausch, Eugen; Schneider, Christof; Ritgen, Matthias; Böttcher, Sebastian; Kreuzer, Karl-Anton; Chyla, Brenda; Miles, Dale; Wendtner, Clemens-Martin; Eich...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 36(2021)
Page Start:
4049
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. Issue 2 (February 2018)

Authors:
DiNardo, Courtney D; Pratz, Keith W; Letai, Anthony; Jonas, Brian A; Wei, Andrew H; Thirman, Michael; Arellano, Martha; Frattini, Mark G; Kantarjian, Hagop; Popovic, Relja; Chyla, Brenda; Xu, Tu; Dunbar, Martin; Agarwal, Suresh K; Humerickhouse, Rod; Mabry, Mack; Potluri, Jalaja; Konopleva, Marin...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 2(2018)
Page Start:
216
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Issue 12 (15th October 2022)

Authors:
Wierda, William G.; Kipps, Thomas J.; Al-Sawaf, Othman; Chyla, Brenda; Biondo, Juliana M. L.; Mun, Yong; Jiang, Yanwen; Seymour, John F.
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 12(2022)
Page Start:
2765
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Issue 1 (January 2018)

Authors:
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G; Davids, Matthew S; Choi, Michael; Cheson, Bruce D; Furman, Richard R; Lamanna, Nicole; Barr, Paul M; Zhou, Lang; Chyla, Brenda; Salem, Ahmed Hamed; Verdugo, Maria; Humerickhouse, Rod A; Potluri, Jalaja; Coutre, Steven; Woyach, Jennifer; Byrd, ...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 1(2018)
Page Start:
65
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Issue 6 (June 2016)

Authors:
Stilgenbauer, Stephan; Eichhorst, Barbara; Schetelig, Johannes; Coutre, Steven; Seymour, John F; Munir, Talha; Puvvada, Soham D; Wendtner, Clemens-Martin; Roberts, Andrew W; Jurczak, Wojciech; Mulligan, Stephen P; Böttcher, Sebastian; Mobasher, Mehrdad; Zhu, Ming; Desai, Monali; Chyla, Brenda; Ve...
Journal:
Lancet oncology
Issue:
Volume 17:Issue 6(2016:Jun.)
Page Start:
768
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. Issue 35 (10th December 2022)

Authors:
Daver, Naval; Perl, Alexander E.; Maly, Joseph; Levis, Mark; Ritchie, Ellen; Litzow, Mark; McCloskey, James; Smith, Catherine C.; Schiller, Gary; Bradley, Terrence; Tiu, Ramon V.; Naqvi, Kiran; Dail, Monique; Brackman, Deanna; Siddani, Satya; Wang, Jing; Chyla, Brenda; Lee, Paul; Altman, Jessica K.
Journal:
Journal of clinical oncology
Issue:
Volume 40:Issue 35(2022)
Page Start:
4048
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗